scholarly journals CD4 + T Cell‐Released Extracellular Vesicles Potentiate the Efficacy of the HBsAg Vaccine by Enhancing B Cell Responses

2019 ◽  
Vol 6 (23) ◽  
pp. 1802219 ◽  
Author(s):  
Jian Lu ◽  
Jing Wu ◽  
Feiting Xie ◽  
Jie Tian ◽  
Xinyi Tang ◽  
...  
1998 ◽  
Vol 72 (7) ◽  
pp. 6138-6145 ◽  
Author(s):  
Narendra Chirmule ◽  
Joseph V. Hughes ◽  
Guang-Ping Gao ◽  
Steven E. Raper ◽  
James M. Wilson

ABSTRACT Adenovirus vectors delivered to lung are being considered in the treatment of cystic fibrosis (CF). Vectors from which E1 has been deleted elicit T- and B-cell responses which confound their use in the treatment of chronic diseases such as CF. In this study, we directly compare the biology of an adenovirus vector from which E1 has been deleted to that of one from which E1 and E4 have been deleted, following intratracheal instillation into mouse and nonhuman primate lung. Evaluation of the E1 deletion vector in C57BL/6 mice demonstrated dose-dependent activation of both CD4 T cells (i.e., TH1 and TH2 subsets) and neutralizing antibodies to viral capsid proteins. Deletion of E4 and E1 had little impact on the CD4 T-cell proliferative response and cytolytic activity of CD8 T cells against target cells expressing viral antigens. Analysis of T-cell subsets from mice exposed to the vector from which E1 and E4 had been deleted demonstrated preservation of TH1 responses with markedly diminished TH2 responses compared to the vector with the deletion of E1. This effect was associated with reduced TH2-dependent immunoglobulin isotypes and markedly diminished neutralizing antibodies. Similar results were obtained in nonhuman primates. These studies indicate that the vector genotype can modify B-cell responses by differential activation of TH1 subsets. Diminished humoral immunity, as was observed with the E1 and E4 deletion vectors in lung, is indeed desired in applications of gene therapy where readministration of the vector is necessary.


2003 ◽  
Vol 198 (7) ◽  
pp. 1011-1021 ◽  
Author(s):  
Mark Y. Sangster ◽  
Janice M. Riberdy ◽  
Maricela Gonzalez ◽  
David J. Topham ◽  
Nicole Baumgarth ◽  
...  

Contact-mediated interactions between CD4+ T cells and B cells are considered crucial for T cell–dependent B cell responses. To investigate the ability of activated CD4+ T cells to drive in vivo B cell responses in the absence of key cognate T–B interactions, we constructed radiation bone marrow chimeras in which CD4+ T cells would be activated by wild-type (WT) dendritic cells, but would interact with B cells that lacked expression of either major histocompatibility complex class II (MHC II) or CD40. B cell responses were assessed after influenza virus infection of the respiratory tract, which elicits a vigorous, CD4+ T cell–dependent antibody response in WT mice. The influenza-specific antibody response was strongly reduced in MHC II knockout and CD40 knockout mice. MHC II–deficient and CD40-deficient B cells in the chimera environment also produced little virus-specific immunoglobulin (Ig)M and IgG, but generated a strong virus-specific IgA response with virus-neutralizing activity. The IgA response was entirely influenza specific, in contrast to the IgG2a response, which had a substantial nonvirus-specific component. Our study demonstrates a CD4+ T cell–dependent, antiviral IgA response that is generated in the absence of B cell signaling via MHC II or CD40, and is restricted exclusively to virus-specific B cells.


PLoS ONE ◽  
2012 ◽  
Vol 7 (3) ◽  
pp. e34377 ◽  
Author(s):  
Aarthi Sundararajan ◽  
Lifang Huan ◽  
Katherine A. Richards ◽  
Glendie Marcelin ◽  
Shabnam Alam ◽  
...  

2016 ◽  
Vol 169 ◽  
pp. 16-27 ◽  
Author(s):  
Geert Leroux-Roels ◽  
Arnaud Marchant ◽  
Jack Levy ◽  
Pierre Van Damme ◽  
Tino F. Schwarz ◽  
...  

PLoS ONE ◽  
2014 ◽  
Vol 9 (7) ◽  
pp. e102284 ◽  
Author(s):  
Christine M. Coquery ◽  
Nekeithia S. Wade ◽  
William M. Loo ◽  
Jason M. Kinchen ◽  
Kelly M. Cox ◽  
...  

2021 ◽  
Author(s):  
Manon Nayrac ◽  
Mathieu Dube ◽  
Geremy Sannier ◽  
Alexandre Nicolas ◽  
Lorie Marchitto ◽  
...  

Spacing of the BNT162b2 mRNA doses beyond 3 weeks raised concerns about vaccine efficacy. We longitudinally analyzed B cell, T cell and humoral responses to two BNT162b2 mRNA doses administered 16 weeks apart in 53 SARS-CoV-2 naive and previously-infected donors. This regimen elicited robust RBD-specific B cell responses whose kinetics differed between cohorts, the second dose leading to increased magnitude in naive participants only. While boosting did not increase magnitude of CD4+ T cell responses further compared to the first dose, unsupervised clustering analyses of single-cell features revealed phenotypic and functional shifts over time and between cohorts. Integrated analysis showed longitudinal immune component-specific associations, with early Thelper responses post-first dose correlating with B cell responses after the second dose, and memory Thelper generated between doses correlating with CD8 T cell responses after boosting. Therefore, boosting elicits a robust cellular recall response after the 16-week interval, indicating functional immune memory.


2017 ◽  
Vol 489 (1) ◽  
pp. 56-62 ◽  
Author(s):  
Eunchong Park ◽  
Myun Soo Kim ◽  
Ju Han Song ◽  
Kyung-Hye Roh ◽  
Rana Lee ◽  
...  

2018 ◽  
Vol 200 (10) ◽  
pp. 3383-3396 ◽  
Author(s):  
Kuan Y. Wong ◽  
Rebecca Baron ◽  
Therese A. Seldon ◽  
Martina L. Jones ◽  
Alison M. Rice ◽  
...  

2016 ◽  
Vol 91 (4) ◽  
Author(s):  
Lilin Ye ◽  
Junghwa Lee ◽  
Lifan Xu ◽  
Ata-Ur-Rasheed Mohammed ◽  
Weiyan Li ◽  
...  

ABSTRACT mTOR has important roles in regulation of both innate and adaptive immunity, but whether and how mTOR modulates humoral immune responses have yet to be fully understood. To address this issue, we examined the effects of rapamycin, a specific inhibitor of mTOR, on B cell and CD4 T cell responses during acute infection with lymphocytic choriomeningitis virus. Rapamycin treatment resulted in suppression of virus-specific B cell responses by inhibiting proliferation of germinal center (GC) B cells. In contrast, the number of memory CD4 T cells was increased in rapamycin-treated mice. However, the drug treatment caused a striking bias of CD4 T cell differentiation into Th1 cells and substantially impaired formation of follicular helper T (Tfh) cells, which are essential for humoral immunity. Further experiments in which mTOR signaling was modulated by RNA interference (RNAi) revealed that B cells were the primary target cells of rapamycin for the impaired humoral immunity and that reduced Tfh formation in rapamycin-treated mice was due to lower GC B cell responses that are essential for Tfh generation. Additionally, we found that rapamycin had minimal effects on B cell responses activated by lipopolysaccharide (LPS), which stimulates B cells in an antigen-independent manner, suggesting that rapamycin specifically inhibits B cell responses induced by B cell receptor stimulation with antigen. Together, these findings demonstrate that mTOR signals play an essential role in antigen-specific humoral immune responses by differentially regulating B cell and CD4 T cell responses during acute viral infection and that rapamycin treatment alters the interplay of immune cell subsets involved in antiviral humoral immunity. IMPORTANCE mTOR is a serine/threonine kinase involved in a variety of cellular activities. Although its specific inhibitor, rapamycin, is currently used as an immunosuppressive drug in transplant patients, it has been reported that rapamycin can also stimulate pathogen-specific cellular immunity in certain circumstances. However, whether and how mTOR regulates humoral immunity are not well understood. Here we found that rapamycin treatment predominantly inhibited GC B cell responses during viral infection and that this led to biased helper CD4 T cell differentiation as well as impaired antibody responses. These findings suggest that inhibition of B cell responses by rapamycin may play an important role in regulation of allograft-specific antibody responses to prevent organ rejection in transplant recipients. Our results also show that consideration of antibody responses is required in cases where rapamycin is used to stimulate vaccine-induced immunity.


Sign in / Sign up

Export Citation Format

Share Document